Helius Medical Technologies, Inc. (HSDT) AI Stock Analysis

Helius Medical Technologies, Inc., based in Newtown, Pennsylvania, is a neurotechnology company focused on developing, licensing, and acquiring non-invasive technologies to treat neurological diseases and trauma. Its core product is the Portable Neuromodulation Stimulator (PoNS), a non-surgical medical device intended for use with supervised therapeutic exercise to address gait deficits from multiple sclerosis and balance deficits from mild-to-moderate traumatic brain injury. The company partners with healthcare professionals and research institutions to expand therapeutic applications for its non-invasive treatment platform.

Revenue increased to $6.0M in FY2025 from $520,000 in FY2024, representing growth of 1057.1%, following years of subdued sales including $522,000 in FY2021, $787,000 in FY2022, and $644,000 in FY2023. Gross margin expanded to 91.7% in FY2025 compared to -11.9% in FY2024. However, net losses widened to -$40.9M in FY2025 from -$11.7M in FY2024, with operating margin at -351.0%. Over the trailing twelve months ended June 30, 2026, revenue stood at $12.1M, supported by quarterly revenue growth of 5774.4% year-over-year, while operating margin was -1293.5%.

As of June 30, 2026, Helius Medical Technologies held $3.6M in cash and short-term investments, total assets of $176.1M, and shareholders' equity of $165.6M, alongside a current ratio of 13.31. In FY2025, operating cash flow was -$16.5M and capital expenditures totaled $44.8M, leading to free cash flow of -$61.3M. In addition, its share count changed by 78254800.0% over 5 years.

With a market capitalization of $145.8M and enterprise value of $173.0M, HSDT trades at a price-to-sales ratio of 12.1x and an EV-to-revenue ratio of 14.3x. By comparison, the median of its US-listed Financial Services peers has a price-to-sales ratio of 3.2x and an EV-to-EBITDA multiple of 11.7x. Over the past year, HSDT stock returned -77.8%, underperforming the S&P 500 (SPY) return of 16.8%, and delivered a 5-year return of -100.0% versus 83.0% for SPY.

Wall Street coverage includes 1 Strong Buy and 1 Buy rating. The mean price target is $3.50, which is 56.2% above the last closing price of $2.24. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $12.2M and an EPS of -$1.71. For next fiscal year, 1 analyst projects revenue of $13.8M, representing 13.1% revenue growth, and an EPS of -$0.11. The company has beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 17, 2026.

This page is an AI-written research summary of Helius Medical Technologies, Inc. (HSDT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HSDT income statement, HSDT balance sheet, HSDT key metrics, HSDT analyst forecast, HSDT chart. See the HSDT stock overview for the latest quote and news.